This can be due to TP53 mutation status being inferred by incomplete sequencing or the assessment method of TP53 mutations being inadequate.19 Further including different histologic subtypes or grades of ovarian cancer combined with lack of robust clinical trial grade outcomes data can influence the conclusions. The gene discussed is TP53; the disease is ovarian carcinoma.